About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
 
  About Us
  Research & Development
  Biopharmaceuticals
  Branded Formulations
  Financial Results
  - Q1FY17 Investor's Concall
  - Investor Presentation
  - Chairman's AGM 2016 Speech
  - Annual Reports
  Facilities Virtual Tour
  Downloads
  - Biocon Profile
  - CMD Profile
  - Video Gallery

Patient Contact

Patient Contact

For more details, please visit:
www.bioconacademy.com

Write to:
admissions@bioconacademy.com


     
 

At Biocon, we are driven by our passion to develop research - driven cutting edge therapies. Our tryst with innovation has enabled us to address the relatively unmet needs of our patients through differentiated products in challenging therapeutic spaces. We have earned the trust of patients and doctors through our products that are safe, efficacious and affordable. We are constantly engaged in pursuit of excellence to find solutions that heal the world.

Biocon is India's largest and fully-integrated, innovation-led biopharmaceutical company. We are committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer.

Through innovative products and research services we are constantly enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. We have successfully developed and taken a range of novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogs from 'Lab to Market'.
Some of our key brands are INSUGEN®(rh-insulin), BASALOG® (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb(Itolizumab), a 'first in class' anti-CD6 monoclonal antibody.

We have a rich pipeline of biosimilars and novel biologics at various stages of development including a high potential Insulin Tregopil.


As the largest Indian Insulins Company, we believe we have made a huge difference to millions of diabetic patients in India. Over the years Biocon has also emerged as a leading Indian oncology company making cancer-care 'affordable' and 'accessible' to patients in India.

read more...


 
   
   
   
 

 

 

Q4FY16 Highlights
Stock Update
 
 
 
 
 
 

  Latest Press Release
 

July 21, 2016:
Biocon Reports a Strong Q1FY17
Revenues at Rs 952 Crore, up by 11 %; EBITDA Up 15% to Rs 271 Crore; Net Profit Up 17% at Rs 147 Crore


July 21, 2016:
Mylan & Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency

Download Annual Report 2016

  Media Coverage
 

July, 2016:
'We need meritocracy, not mediocrity' - Kiran Mazumdar Shaw

Apr 28, 2016:
Biocon Q4FY16 Net Profit up 79% to Rs. 361 crore

 

Biocon Foundation


eLaj - Primary Healthcare


Biocon Malaysia

     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2016, Biocon. All Rights Reserved